<DOC>
	<DOCNO>NCT01568060</DOCNO>
	<brief_summary>The purpose study collect safety information follow routine vaccination Infanrix-IPV among infant child Korea .</brief_summary>
	<brief_title>Post-marketing Surveillance Assess Safety Infanrix-IPV Vaccine Among Infants Children Korea</brief_title>
	<detailed_description />
	<mesh_term>Whooping Cough</mesh_term>
	<mesh_term>Tetanus</mesh_term>
	<mesh_term>Tetany</mesh_term>
	<mesh_term>Diphtheria</mesh_term>
	<mesh_term>Poliomyelitis</mesh_term>
	<criteria>Subjects investigator believe parent ( ) /legally acceptable representative ( ) comply requirement protocol . Korean male female subject eligible primary and/or booster dose InfanrixIPV accord Korean Prescribing Information . Written sign inform consent obtain parent ( ) / legally acceptable representative ( ) child . Where parent ( ) / legally acceptable representative illiterate , consent form countersign impartial witness . Prior enrollment subject postmarketing surveillance , subject 's parents/legally acceptable representative request provide information regard enrollment child same/similar study previously . And prior obtaining inform consent form , investigator check whether subject eligible vaccination . At time postmarketing surveillance ( PMS ) entry , contraindication precaution use indicated local Prescribing Information check subject must include PMS contraindication . Any change locally approve Prescribing Information must implement immediately . Subjects receive investigational nonlicensed DTPaIPV vaccine within 30 day prior study start enrol . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>2 Months</minimum_age>
	<maximum_age>6 Years</maximum_age>
	<verification_date>April 2016</verification_date>
	<keyword>Safety</keyword>
	<keyword>Infanrix-IPV</keyword>
	<keyword>Post-marketing surveillance</keyword>
	<keyword>Diphtheria , tetanus , pertussis poliomyelitis</keyword>
</DOC>